Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM,CHEK2, NBN,BRIP1, RAD51C,and RAD51D results on patient management and adherence to provider recommendations |
| |
| Authors: | Valentina Vysotskaia PhD K. Eerik Kaseniit MEng Leslie Bucheit MS CGC Kaylene Ready MS CGC Kristin Price MS CGC Katherine Johansen Taber PhD |
| |
| Affiliation: | 1. Myriad Women's Health, South San Francisco, California;2. Myriad Genetics, Salt Lake City, Utah;3. Counsyl, Inc., South San Fancisco, California |
| |
| Abstract: | |
| |
| Keywords: | breast cancer cancer risk colorectal cancer hereditary cancer ovarian cancer |
|
|
